REVIEW PAPER
Ceragenins – a new weapon to fight multidrug resistant bacterial infections
Submission date: 2014-06-16
Final revision date: 2014-07-04
Acceptance date: 2014-07-04
Publication date: 2014-09-19
Medical Studies 2014;30(3):207-213
KEYWORDS
TOPICS
ABSTRACT
Growing antibiotic resistance among pathogenic microorganisms is one of the most challenging problems. Often, a single mutation in a bacterial cell leads to the formation of a new drug resistance mechanism. The ceragenins are a novel class of antibiotic, offering great promise in future treatment of infections. These cationic antimicrobial lipids are net positively charged cholic acid derivates that are electrostatically attracted to the negatively charged membranes of bacteria, certain viruses, fungi, and protozoa. After membrane insertion, they interfere with membrane organisation, resulting in membrane dysfunction and cell death. This review focuses on the broad spectrum of antibacterial activity of ceragenins, and their potential to become a new group of antibiotics for prevention and treatment of infections, especially those caused by multidrug-resistant bacteria.
REFERENCES (52)
1.
Khanna S, Tosh PK. A clinician’s primer on the role of the microbiome in human health and disease. Mayo Clin Proc 2014; 89: 107-14.
2.
Shoham S, Shah PD. Impact of multidrug-resistant organisms on patients considered for lung transplantation. Infect Dis Clin North Am 2013; 27: 343-58.
3.
Calfee DP. Multidrug-resistant organisms in dialysis patients. Semin Dial 2013; 26: 447-56.
4.
Zignol M, Dara M, Dean AS, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist Updat 2013; 16: 108-15.
5.
Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013; 368: 745-55.
6.
Mshana SE, Matee M, Rweyemamu M. Antimicrobial resistance in human and animal pathogens in Zambia, Democratic Republic of Congo, Mozambique and Tanzania: an urgent need of a sustainable surveillance system. Ann Clin Microbiol Antimicrob 2013; 12: 28.
7.
Kang CI, Song JH. Antimicrobial resistance in Asia: current epidemiology and clinical implications. Infect Chemother 2013; 45: 22-31.
8.
Mathur P, Singh S. Multidrug resistance in bacteria: a serious patient safety challenge for India. J Lab Physicians 2013; 5: 5-10.
9.
Salles MJ, Zurita J, Mejía C, et al. Resistant gram-negative infections in the outpatient setting in Latin America. Epidemiol Infect 2013; 141: 2459-72.
10.
Paphitou NI. Antimicrobial resistance: action to combat the rising microbial challenges. Int J Antimicrob Agents 2013; 42 Suppl: S25-8.
11.
Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol 2013; 31: 177-84.
12.
Nagant C, Feng Y, Lucas B, et al. Effect of a low concentration of a cationic steroid antibiotic (CSA-13) on the formation of a biofilm by Pseudomonas aeruginosa. J Appl Microbiol 2011; 111: 763-72.
13.
Moore KS, Wehrli S, Roder H, et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci U S A1993; 90: 1354-8.
14.
Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A 1987; 84: 5449-53.
15.
Zasloff M. Antimicrobial peptides in health and disease. N Engl J Med 2002; 347: 1199-200.
16.
Ding B, Taotofa U, Orsak T, et al. Synthesis and characterization of peptide-cationic steroid antibiotic conjugates. Org Lett 2004; 6: 3433-6.
17.
Epand RM, Epand RF, Savage PB. Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents. Drug News Perspect 2008; 21: 307-11.
18.
Pollard JE, Snarr J, Chaudhary V, et al. In vitro evaluation of the potential for resistance development to ceragenin CSA-13. J Antimicrob Chemother 2012; 67: 2665-72.
19.
Lai XZ, Feng Y, Pollard J, et al. Ceragenins: cholic acidbased mimics of antimicrobial peptides. Acc Chem Res 2008; 41: 1233-40.
20.
Van Bambeke F, Mingeot-Leclercq MP, Struelens MJ, Tulkens PM. The bacterial envelope as a target for novel antiMRSA antibiotics. Trends Pharmacol Sci 2008; 29: 124-34.
21.
Bellini AM, Vertuani G, Quaglio MP, Cavazzini G. Bile acid derivatives with antimicrobial activity. Farmaco Sci 1979; 34: 967-78.
22.
Zanetti M, Gennaro R, Scocchi M, Skerlavaj B. Structure and biology of cathelicidins. Adv Exp Med Biol 2000; 479: 203-18.
23.
Bucki R, Pastore JJ, Randhawa P, et al. Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin. Antimicrob Agents Chemother 2004; 48: 1526-33.
24.
Savage PB, Li C, Taotafa U, et al. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett 2002; 217: 1-7.
25.
Deng G, Dewa T, Regen SL. A synthetic ionophore that recognizes negatively charged phospholipid membranes. J Am Chem Soc 1996; 118: 8975-6.
26.
Chin JN, Jones RN, Sader HS, et al. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother 2008; 61: 365-70.
27.
Chin JN, Rybak MJ, Cheung CM, Savage PB. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 1268-73.
28.
Leszczynska K, Namiot A, Fein DE, et al. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiol 2009; 9: 187.
29.
Bozkurt-Guzel C, Savage PB, Akcali A, Ozbek-Celik B. Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant Acinetobacter baumannii strains isolated from bacteremia patients. Biomed Res Int 2014; 2014: 710273.
30.
Isogai E, Isogai H, Takahashi K, et al. Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria. Oral Microbiol Immunol 2009; 24: 170-2.
31.
Howell MD, Streib JE, Kim BE, et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. J Invest Dermatol 2009; 129: 2668-75.
32.
Lara D, Feng Y, Bader J, et al. Anti-trypanosomatid activity of ceragenins. J Parasitol 2010; 96: 638-42.
33.
Hoppens MA, Wheeler ZE, Qureshi AT, et al. Maghemite, silver, ceragenin conjugate particles for selective binding and contrast of bacteria. J Colloid Interface Sci 2014; 413: 167-74.
34.
Gu X, Jennings JD, Snarr J, et al. Optimization of ceragenins for prevention of bacterial colonization of hydrogel contact lenses. Invest Ophthalmol Vis Sci 2013; 54: 6217-23.
35.
Sinclair KD, Pham TX, Williams DL, et al. Model development for determining the efficacy of a combination coating for the prevention of perioperative device related infections: a pilot study. J Biomed Mater Res B Appl Biomater 2013; 101: 1143-53.
36.
Williams DL, Sinclair KD, Jeyapalina S, Bloebaum RD. Characterization of a novel active release coating to prevent biofilm implant-related infections. J Biomed Mater Res B Appl Biomater 2013; 101: 1078-89.
37.
Sinclair KD, Pham TX, Farnsworth RW, et al. Development of a broad spectrum polymer-released antimicrobial coating for the prevention of resistant strain bacterial infections. J Biomed Mater Res A 2012; 100: 2732-8.
38.
Kichler A, Leborgne C, Savage PB, Danos O. Cationic steroid antibiotics demonstrate DNA delivery properties.J Control Release 2005; 107: 174-82.
39.
Kuroda K, Fukuda T, Okumura K, et al. Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells. Anticancer Drugs 2013; 24: 826-34.
40.
Saha S, Savage PB, Bal M. Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gramnegative bacterial pathogens. J Appl Microbiol 2008; 105: 822-8.
41.
Dhooghe B, Noël S, Huaux F, Leal T. Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clin Biochem 2014; 47: 539-46.
42.
Rosenthal KL. Tweaking innate immunity: the promise of innate immunologicals as anti-infectives. Can J Infect Dis Med Microbiol 2006; 17: 307-14.
43.
Bucki R, Sostarecz AG, Byfield FJ, et al. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J Antimicrob Chemother 2007; 60: 535-45.
44.
Leszczynska K, Namiot D, Byfield FJ, et al. Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections. J Antimicrob Chemother 2013; 68: 610-8.
45.
Rodríguez-Rojas A, Oliver A, Blázquez J. Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. J Infect Dis 2012; 205: 121-7.
46.
Alhede M, Bjarnsholt T, Givskov M. Pseudomonas aeruginosa biofilms: mechanisms of immune evasion. Adv Appl Microbiol 2014; 86: 1-40.
47.
Walker TS, Tomlin KL, Worthen GS, et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 2005; 73: 3693-701.
48.
Parks QM, Young RL, Poch KR, et al. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J Med Microbiol 2009; 58: 492-502.
49.
Moreau-Marquis S, Stanton BA, O’Toole GA. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm Pharmacol Ther 2008; 21: 595-9.
50.
Döring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-67.
51.
Nagant C, Pitts B, Stewart PS, et al. Study of the effect of antimicrobial peptide mimic, CSA-13, on an established biofilm formed by Pseudomonas aeruginosa. Microbiologyopen 2013; 2: 318-25.
52.
Bozkurt-Guzel C, Savage PB, Gerceker AA. In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy 2011; 57: 505-10.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
